Literature DB >> 14500366

Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.

Angelo Agathanggelou1, Ivan Bièche, Jalal Ahmed-Choudhury, Barbara Nicke, Reinhard Dammann, Shairaz Baksh, Boning Gao, John D Minna, Julian Downward, Eamonn R Maher, Farida Latif.   

Abstract

RASSF1A is a recently identified 3p21.3 tumor suppressor gene. The high frequency of epigenetic inactivation of this gene in a wide range of human sporadic cancers including non-small cell lung cancer (NSCLC) and neuroblastoma suggests that RASSF1A inactivation is important for tumor development. Although little is known about the function of RASSF1A, preliminary data suggests that it may have multiple functions. To gain insight into RASSF1A functions in an unbiased manner, we have characterized the expression profile of a lung cancer cell line (A549) transfected with RASSF1A. Initially we demonstrated that transient expression of RASSF1A into the NSCLC cell line A549 induced G(1) cell cycle arrest, as measured by propidium iodide staining. Furthermore, annexin-V staining showed that RASSF1A-expressing cells had an increased sensitivity to staurosporine-induced apoptosis. We then screened a cDNA microarray containing more than 6000 probes to identify genes differentially regulated by RASSF1A. Sixty-six genes showed at least a 2-fold change in expression. Among these were many genes with relevance to tumorigenesis involved in transcription, cytoskeleton, signaling, cell cycle, cell adhesion, and apoptosis. For 22 genes we confirmed the microarray results by real-time RT-PCR and/or Northern blotting. In silico, we were able to confirm the majority of these genes in other NSCLC cell lines using published data on gene expression profiles. Furthermore, we confirmed 10 genes at the RNA level in two neuroblastoma cell lines, indicating that these RASSF1A target genes have relevance in non-lung cell backgrounds. Protein analysis of six genes (ETS2, Cyclin D3, CDH2, DAPK1, TXN, and CTSL) showed that the changes induced by RASSF1A at the RNA level correlated with changes in protein expression in both non-small cell lung cancer and neuroblastoma cell lines. Finally, we have used a transient assay to demonstrate the induction of CDH2 and TGM2 by RASSF1A in NSCLC cell lines. We have identified several novel targets for RASSF1A tumor suppressor gene both at the RNA and the protein levels in two different cellular backgrounds. The identified targets are involved in diverse cellular processes; this should help toward understanding mechanisms that contribute to RASSF1A biological activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500366      PMCID: PMC3484890     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Identification of a single nucleotide polymorphism in the human alpha 2 delta 2 calcium channel subunit gene.

Authors:  S Honorio; K Gordon; D MacCartney; A Agathanggelou; F Latif
Journal:  Mol Cell Probes       Date:  2001-12       Impact factor: 2.365

2.  The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1.

Authors:  Sara Ortiz-Vega; Andrei Khokhlatchev; Maria Nedwidek; Xian-feng Zhang; Reinhard Dammann; Gerd P Pfeifer; Joseph Avruch
Journal:  Oncogene       Date:  2002-02-21       Impact factor: 9.867

3.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer.

Authors:  Manon van Engeland; Guido M J M Roemen; Mirian Brink; Marco M M Pachen; Matty P Weijenberg; Adriaan P de Bruïne; Jan-Willem Arends; Piet A van den Brandt; Anton F P M de Goeij; James G Herman
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

Review 4.  The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis.

Authors:  Roy M Bremnes; Robert Veve; Fred R Hirsch; Wilbur A Franklin
Journal:  Lung Cancer       Date:  2002-05       Impact factor: 5.705

5.  Identification of a novel Ras-regulated proapoptotic pathway.

Authors:  Andrei Khokhlatchev; Shahrooz Rabizadeh; Ramnik Xavier; Maria Nedwidek; Tao Chen; Xian-feng Zhang; Brian Seed; Joseph Avruch
Journal:  Curr Biol       Date:  2002-02-19       Impact factor: 10.834

6.  The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.

Authors:  Latha Shivakumar; John Minna; Toshiyuki Sakamaki; Richard Pestell; Michael A White
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

7.  SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.

Authors:  Alexandre Chlenski; Shuqing Liu; Susan E Crawford; Olga V Volpert; George H DeVries; Amy Evangelista; Qiwei Yang; Helen R Salwen; Robert Farrer; James Bray; Susan L Cohn
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

8.  Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.

Authors:  Sofia Honorio; Angelo Agathanggelou; Nicolas Wernert; Marcus Rothe; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

9.  Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition.

Authors:  Nirada Dhanesuan; Julie A Sharp; Tony Blick; John T Price; Erik W Thompson
Journal:  Breast Cancer Res Treat       Date:  2002-09       Impact factor: 4.872

10.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.

Authors:  Igor Kuzmin; John W Gillespie; Alexei Protopopov; Laura Geil; Koen Dreijerink; Youfeng Yang; Cathy D Vocke; Fuh-Mei Duh; Eugene Zabarovsky; John D Minna; Johng S Rhim; Michael R Emmert-Buck; W Marston Linehan; Michael I Lerman
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  31 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 2.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

3.  Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.

Authors:  Andrea Cornero; Massimo Acquaviva; Paolo Fardin; Rogier Versteeg; Alexander Schramm; Alessandra Eva; Maria Carla Bosco; Fabiola Blengio; Sara Barzaghi; Luigi Varesio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

4.  ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.

Authors:  Ignacio I Wistuba; Humam Kadara; Mohamed Kabbout; Melinda M Garcia; Junya Fujimoto; Diane D Liu; Denise Woods; Chi-Wan Chow; Gabriela Mendoza; Amin A Momin; Brian P James; Luisa Solis; Carmen Behrens; J Jack Lee
Journal:  Clin Cancer Res       Date:  2013-05-09       Impact factor: 12.531

5.  Incorporating network structure in integrative analysis of cancer prognosis data.

Authors:  Jin Liu; Jian Huang; Shuangge Ma
Journal:  Genet Epidemiol       Date:  2012-11-17       Impact factor: 2.135

6.  Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.

Authors:  Victoria Lladó; Silvia Terés; Mónica Higuera; Rafael Alvarez; Maria Antònia Noguera-Salva; John E Halver; Pablo V Escribá; Xavier Busquets
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

7.  Menin determines K-RAS proliferative outputs in endocrine cells.

Authors:  Chester E Chamberlain; David W Scheel; Kathleen McGlynn; Hail Kim; Takeshi Miyatsuka; Juehu Wang; Vinh Nguyen; Shuhong Zhao; Anastasia Mavropoulos; Aswin G Abraham; Eric O'Neill; Gregory M Ku; Melanie H Cobb; Gail R Martin; Michael S German
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

8.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

9.  Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis.

Authors:  Mark E Reeves; Scott W Baldwin; Melissa L Baldwin; Shin-Tai Chen; Jeremy M Moretz; Robert J Aragon; Xinmin Li; Donna D Strong; Subburaman Mohan; Yousef G Amaar
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

10.  The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China.

Authors:  Geqiong Xiao; Tao Zhang; Jie Yao; Jinghua Ren; Wenmiao Cao; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.